In 2015, palbociclib was approved by the FDA, not for protection of normal cells but for the treatment of estrogen receptor (ER)-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy in postmenopausal women. This evidence concerns the gene ESR1 and breast cancer.